Latest News
Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis
11 March 2022
Monday, March 14th @ 11 am ET, registration details below
NEW YORK, March 11, 2022 – Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced today that...
Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody
10 March 2022
- Intranasal foralumab was well-tolerated with no adverse reactions or laboratory abnormalities after 6 months of therapy and the patient chose to remain on therapy
- Data show sustained inhibition of microglial activation as assessed by Positron Emission Tomography (PET) along with downregulation...
KOL Event - 14 March 2022 at 11am ET
04 March 2022
StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort
01 March 2022
New York, March 1, 2022 - Tiziana Life Sciences Ltd.’s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today announced publication of new data in the European Journal of Cancer. Results demonstrate that StemPrintER...
Tiziana Life Science's Presentation at the Bio CEO & Investor Conference 2022
11 February 2022
Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference
10 February 2022
February 10, 2022, New York, NY – Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced today that Dr Kunwar Shailubhai, Chief Executive Officer and Chief...